These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. An Adjuvanted, Postfusion F Protein-Based Vaccine Did Not Prevent Respiratory Syncytial Virus Illness in Older Adults. Falloon J; Yu J; Esser MT; Villafana T; Yu L; Dubovsky F; Takas T; Levin MJ; Falsey AR J Infect Dis; 2017 Dec; 216(11):1362-1370. PubMed ID: 29029260 [TBL] [Abstract][Full Text] [Related]
8. Current progress on development of respiratory syncytial virus vaccine. Chang J BMB Rep; 2011 Apr; 44(4):232-7. PubMed ID: 21524347 [TBL] [Abstract][Full Text] [Related]
9. Immunopathology of RSV infection: prospects for developing vaccines without this complication. van Drunen Littel-van den Hurk S; Mapletoft JW; Arsic N; Kovacs-Nolan J Rev Med Virol; 2007; 17(1):5-34. PubMed ID: 17004293 [TBL] [Abstract][Full Text] [Related]
10. Respiratory syncytial virus-specific cell-mediated immune responses after vaccination with a purified fusion protein subunit vaccine. Welliver RC; Tristram DA; Batt K; Sun M; Hogerman D; Hildreth S J Infect Dis; 1994 Aug; 170(2):425-8. PubMed ID: 8035030 [TBL] [Abstract][Full Text] [Related]
11. Protection against respiratory syncytial virus infection by DNA immunization. Li X; Sambhara S; Li CX; Ewasyshyn M; Parrington M; Caterini J; James O; Cates G; Du RP; Klein M J Exp Med; 1998 Aug; 188(4):681-8. PubMed ID: 9705950 [TBL] [Abstract][Full Text] [Related]
12. Induction of mucosal and systemic immunity against respiratory syncytial virus by inactivated virus supplemented with TLR9 and NOD2 ligands. Shafique M; Wilschut J; de Haan A Vaccine; 2012 Jan; 30(3):597-606. PubMed ID: 22120195 [TBL] [Abstract][Full Text] [Related]
13. A Randomized, Controlled, Observer-Blinded Phase 1 Study of the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine With or Without Alum Adjuvant. Langley JM; Aggarwal N; Toma A; Halperin SA; McNeil SA; Fissette L; Dewé W; Leyssen M; Toussaint JF; Dieussaert I J Infect Dis; 2017 Jan; 215(1):24-33. PubMed ID: 27694633 [TBL] [Abstract][Full Text] [Related]
14. [Prevention of respiratory syncytial virus infection in a peripheral hospital: economic problems and ethical questions]. Faverge B; Bonein M; Attou D; Benskhria S; Gratecos L Arch Pediatr; 2000 Apr; 7(4):429. PubMed ID: 10793937 [No Abstract] [Full Text] [Related]
15. A Single-Dose Recombinant Parainfluenza Virus 5-Vectored Vaccine Expressing Respiratory Syncytial Virus (RSV) F or G Protein Protected Cotton Rats and African Green Monkeys from RSV Challenge. Wang D; Phan S; DiStefano DJ; Citron MP; Callahan CL; Indrawati L; Dubey SA; Heidecker GJ; Govindarajan D; Liang X; He B; Espeseth AS J Virol; 2017 Jun; 91(11):. PubMed ID: 28298602 [TBL] [Abstract][Full Text] [Related]
16. Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3. Schmidt AC; McAuliffe JM; Murphy BR; Collins PL J Virol; 2001 May; 75(10):4594-603. PubMed ID: 11312329 [TBL] [Abstract][Full Text] [Related]
17. Advances in and the potential of vaccines for respiratory syncytial virus. Jorquera PA; Oakley KE; Tripp RA Expert Rev Respir Med; 2013 Aug; 7(4):411-27. PubMed ID: 23964629 [TBL] [Abstract][Full Text] [Related]